|
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD
|
30 April 2025 |
|
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan)
|
08 August 2024 |
|
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
|
07 May 2024 |
|
Novartis presents new data on safety and efficacy of Zolgensma
|
04 March 2024 |
|
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
|
21 September 2023 |
|
Novartis completes acquisition of Chinook Therapeutics
|
28 August 2023 |
|
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
|
19 July 2023 |
|
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
|
27 March 2023 |
|
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
|
17 March 2023 |
|
Novartis invests in early technical development capabilities for next-generation biotherapeutics
|
12 September 2022 |